| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL ARTICLES |
From the Departments of Surgical Oncology (BWF, PWTP, PFM), Digestive Diseases (JAA), and Radiation Therapy (TAR), The University of Texas, M.D. Anderson Cancer Center, Houston, Texas; and the Department of Surgical Oncology (AML), University of Cincinnati, Cincinnati, Ohio.
Correspondence: Address correspondence and reprint requests to: Paul F. Mansfield, MD, Department of Surgical Oncology, Box 106, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030; Fax: 713-792-0722; E-mail: pmansfie{at}notes.mdacc.tmc.edu
Background: The goals of this study were to assess the feasibility and toxicity of a regimen of preoperative chemoradiotherapy, surgery, and intraoperative radiotherapy in the treatment of patients with potentially resectable gastric cancer. A secondary objective was to assess pathologic response to chemoradiotherapy in the treated tumors.
Methods: Twenty-four patients were entered in the protocol. Treatment regimen consisted of 45 Gy of external beam radiotherapy with concurrent 5-FU given as a continuous infusion at a dose of 300 mg/m2. Patients were restaged 4–6 weeks after chemoradiotherapy and then underwent surgical resection and intraoperative radiotherapy to a dose of 10 Gy.
Results: Twenty-three patients (96%) completed chemoradiotherapy in accordance with the study protocol. Nineteen (83%) of 23 patients who completed chemoradiotherapy underwent surgical resection with D2 lymphadenectomy. Four patients (17%) had progressive disease and were not resected. The morbidity and mortality rates were 32% and 5%, respectively. Of the resected patients, two (11%) had complete pathologic responses while 12 (63%) had pathologic evidence of significant treatment effect.
Conclusions: Preoperative chemoradiotherapy for gastric cancer can be delivered safely and is well tolerated. The rate of surgical complications is consistent with that of other recently reported prospective trials of gastrectomy alone. Preoperative chemoradiotherapy resulted in significant pathologic responses in the majority of treated tumors, and complete pathologic responses were achieved in some patients.
Key Words: Preoperative chemoradiotherapy • Gastric cancer
This article has been cited by other articles:
 |
|
 |
|
  K. Fujitani, J. A. Ajani, C. H. Crane, B. W. Feig, P. W. Pisters, N. Janjan, G. L. Walsh, S. G. Swisher, A. A. Vaporciyan, D. Rice, et al. Impact of Induction Chemotherapy and Preoperative Chemoradiotherapy on Operative Morbidity and Mortality in Patients with Locoregional Adenocarcinoma of the Stomach or Gastroesophageal Junction Ann. Surg. Oncol., July 1, 2007; 14(7): 2010 - 2017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bentrem, H. Gerdes, L. Tang, M. Brennan, and D. Coit Clinical Correlation of Endoscopic Ultrasonography with Pathologic Stage and Outcome in Patients Undergoing Curative Resection for Gastric Cancer Ann. Surg. Oncol., June 1, 2007; 14(6): 1853 - 1859. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fujitani, J. A. Ajani, C. H. Crane, B. W. Feig, P. W. Pisters, N. Janjan, G. L. Walsh, S. G. Swisher, A. A. Vaporciyan, D. Rice, et al. Impact of Induction Chemotherapy and Preoperative Chemoradiotherapy on Operative Morbidity and Mortality in Patients with Locoregional Adenocarcinoma of the Stomach or Gastroesophageal Junction Ann. Surg. Oncol., April 1, 2007; 14(4): 1305 - 1311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lim, M. Michael, G. B. Mann, and T. Leong Adjuvant Therapy in Gastric Cancer J. Clin. Oncol., September 1, 2005; 23(25): 6220 - 6232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Napieralski, K. Ott, M. Kremer, K. Specht, H. Vogelsang, K. Becker, M. Muller, F. Lordick, U. Fink, J. Rudiger Siewert, et al. Combined GADD45A and Thymidine Phosphorylase Expression Levels Predict Response and Survival of Neoadjuvant-Treated Gastric Cancer Patients Clin. Cancer Res., April 15, 2005; 11(8): 3025 - 3031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.A. Ajani, P.F. Mansfield, N. Janjan, J. Morris, P.W. Pisters, P.M. Lynch, B. Feig, R. Myerson, R. Nivers, D.S. Cohen, et al. Multi-Institutional Trial of Preoperative Chemoradiotherapy in Patients With Potentially Resectable Gastric Carcinoma J. Clin. Oncol., July 15, 2004; 22(14): 2774 - 2780. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Rich, R. C. Shepard, and S. T. Mosley Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy J. Clin. Oncol., June 1, 2004; 22(11): 2214 - 2232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Nitti, A. Marchet, M. Olivieri, A. Ambrosi, R. Mencarelli, C. Belluco, and M. Lise Ratio Between Metastatic and Examined Lymph Nodes Is an Independent Prognostic Factor After D2 Resection for Gastric Cancer: Analysis of a Large European Monoinstitutional Experience Ann. Surg. Oncol., November 1, 2003; 10(9): 1077 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Ota A Pilot Study of Preoperative Chemoradiation for Gastric Cancer Ann. Surg. Oncol., July 1, 2001; 8(6): 482 - 483. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
